Nu Skin's Stock Keeps Getting Cheaper, But Analyst Says Don't Buy Yet

Nu Skin Enterprises' stock extended its post-earnings tumble by shedding 7.3% Thursday, to close at the lowest level since Feb. 27, 2013. The stock has now lost 19.6% since the direct marketer of anti-aging cream provided a disappointing fourth-quarter outlook ahead of Wednesday's open, citing weakness in China and unfavorable currency fluctuations. Analyst Scott Van Winkle at Canaccord Genuity kept his rating on the stock at hold, but cut his price target to $45 from $53. "We believe a stabilization and month-over-month growth in China are necessary before the shares can be bought, despite the heavily discounted valuation," Van Winkle wrote in a note to clients. The stock has now lost 71% so far this year, compared with a 9.9% gain in the S&P 500.